Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

PTN vs ANIP vs PRGO vs INVA

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
PTN
Palatin Technologies, Inc.

Biotechnology

HealthcareAMEX • US
Market Cap$10M
5Y Perf.+48.2%
ANIP
ANI Pharmaceuticals, Inc.

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • US
Market Cap$1.78B
5Y Perf.+170.2%
PRGO
Perrigo Company plc

Drug Manufacturers - Specialty & Generic

HealthcareNYSE • IE
Market Cap$1.61B
5Y Perf.-78.6%
INVA
Innoviva, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$1.93B
5Y Perf.+63.2%

PTN vs ANIP vs PRGO vs INVA — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
PTN logoPTN
ANIP logoANIP
PRGO logoPRGO
INVA logoINVA
IndustryBiotechnologyDrug Manufacturers - Specialty & GenericDrug Manufacturers - Specialty & GenericBiotechnology
Market Cap$10M$1.78B$1.61B$1.93B
Revenue (TTM)$9M$883M$4.18B$424M
Net Income (TTM)$-10M$78M$-1.82B$504M
Gross Margin99.2%69.1%34.2%76.2%
Operating Margin-134.8%12.6%-4.1%14.8%
Forward P/E9.2x5.6x11.9x
Total Debt$164K$325M$3.97B$269M
Cash & Equiv.$3M$286M$532M$551M

PTN vs ANIP vs PRGO vs INVALong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

PTN
ANIP
PRGO
INVA
StockMay 20May 26Return
Palatin Technologie… (PTN)100148.2+48.2%
ANI Pharmaceuticals… (ANIP)100270.2+170.2%
Perrigo Company plc (PRGO)10021.4-78.6%
Innoviva, Inc. (INVA)100163.2+63.2%

Price return only. Dividends and distributions are not included.

Quick Verdict: PTN vs ANIP vs PRGO vs INVA

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: INVA leads in 3 of 7 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Perrigo Company plc is the stronger pick specifically for valuation and capital efficiency and dividend income and shareholder returns. PTN and ANIP also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
PTN
Palatin Technologies, Inc.
The Momentum Pick

PTN is the clearest fit if your priority is momentum.

  • +199.9% vs PRGO's -51.2%
Best for: momentum
ANIP
ANI Pharmaceuticals, Inc.
The Growth Play

ANIP is the clearest fit if your priority is growth exposure.

  • Rev growth 43.8%, EPS growth 419.2%, 3Y rev CAGR 40.8%
  • 43.8% revenue growth vs PTN's -100.0%
Best for: growth exposure
PRGO
Perrigo Company plc
The Income Pick

PRGO is the #2 pick in this set and the best alternative if income & stability is your priority.

  • Dividend streak 10 yrs, beta 1.18, yield 9.8%
  • Lower P/E (5.6x vs 11.9x)
  • 9.8% yield, 10-year raise streak, vs ANIP's 0.1%, (2 stocks pay no dividend)
Best for: income & stability
INVA
Innoviva, Inc.
The Long-Run Compounder

INVA carries the broadest edge in this set and is the clearest fit for long-term compounding and sleep-well-at-night.

  • 94.9% 10Y total return vs ANIP's 84.7%
  • Lower volatility, beta 0.13, Low D/E 22.9%, current ratio 14.64x
  • Beta 0.13, current ratio 14.64x
  • 118.9% margin vs PTN's -107.4%
Best for: long-term compounding and sleep-well-at-night
See the full category breakdown
CategoryWinnerWhy
GrowthANIP logoANIP43.8% revenue growth vs PTN's -100.0%
ValuePRGO logoPRGOLower P/E (5.6x vs 11.9x)
Quality / MarginsINVA logoINVA118.9% margin vs PTN's -107.4%
Stability / SafetyINVA logoINVABeta 0.13 vs PRGO's 1.18, lower leverage
DividendsPRGO logoPRGO9.8% yield, 10-year raise streak, vs ANIP's 0.1%, (2 stocks pay no dividend)
Momentum (1Y)PTN logoPTN+199.9% vs PRGO's -51.2%
Efficiency (ROA)INVA logoINVA32.4% ROA vs PTN's -53.7%

PTN vs ANIP vs PRGO vs INVA — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

PTNPalatin Technologies, Inc.
FY 2022
Product Revenue
100.0%$1M
ANIPANI Pharmaceuticals, Inc.
FY 2024
Total Sales of Generics and Other
52.1%$320M
Sales of rare disease pharmaceutical products
37.4%$230M
Sales of Established Brands
10.5%$65M
PRGOPerrigo Company plc
FY 2025
Consumer Self-Care Americas
60.8%$2.6B
Consumer Self-Care International
39.2%$1.7B
INVAInnoviva, Inc.
FY 2025
Royalty
57.5%$236M
Product
41.8%$172M
License And Other Revenue
0.7%$3M

PTN vs ANIP vs PRGO vs INVA — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLINVALAGGINGANIP

Income & Cash Flow (Last 12 Months)

INVA leads this category, winning 4 of 6 comparable metrics.

PRGO is the larger business by revenue, generating $4.2B annually — 466.2x PTN's $9M. INVA is the more profitable business, keeping 118.9% of every revenue dollar as net income compared to PTN's -107.4%. On growth, ANIP holds the edge at +29.6% YoY revenue growth, suggesting stronger near-term business momentum.

MetricPTN logoPTNPalatin Technolog…ANIP logoANIPANI Pharmaceutica…PRGO logoPRGOPerrigo Company p…INVA logoINVAInnoviva, Inc.
RevenueTrailing 12 months$9M$883M$4.2B$424M
EBITDAEarnings before interest/tax-$12M$203M$58M$86M
Net IncomeAfter-tax profit-$10M$78M-$1.8B$504M
Free Cash FlowCash after capex-$16M$128M$108M$181M
Gross MarginGross profit ÷ Revenue+99.2%+69.1%+34.2%+76.2%
Operating MarginEBIT ÷ Revenue-134.8%+12.6%-4.1%+14.8%
Net MarginNet income ÷ Revenue-107.4%+8.9%-43.5%+118.9%
FCF MarginFCF ÷ Revenue-177.2%+14.5%+2.6%+42.8%
Rev. Growth (YoY)Latest quarter vs prior year+29.6%-7.2%+10.6%
EPS Growth (YoY)Latest quarter vs prior year-19.7%+3.1%-56.4%+4.0%
INVA leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

PRGO leads this category, winning 5 of 6 comparable metrics.

At 6.9x trailing earnings, INVA trades at a 73% valuation discount to ANIP's 25.3x P/E. On an enterprise value basis, PRGO's 7.4x EV/EBITDA is more attractive than ANIP's 9.0x.

MetricPTN logoPTNPalatin Technolog…ANIP logoANIPANI Pharmaceutica…PRGO logoPRGOPerrigo Company p…INVA logoINVAInnoviva, Inc.
Market CapShares × price$10M$1.8B$1.6B$1.9B
Enterprise ValueMkt cap + debt − cash$8M$1.8B$5.1B$1.7B
Trailing P/EPrice ÷ TTM EPS-0.59x25.27x-1.14x6.91x
Forward P/EPrice ÷ next-FY EPS est.9.25x5.56x11.91x
PEG RatioP/E ÷ EPS growth rate0.67x
EV / EBITDAEnterprise value multiple8.99x7.42x8.10x
Price / SalesMarket cap ÷ Revenue2.02x0.38x4.55x
Price / BookPrice ÷ Book value/share3.29x0.55x1.65x
Price / FCFMarket cap ÷ FCF9.62x11.12x9.88x
PRGO leads this category, winning 5 of 6 comparable metrics.

Profitability & Efficiency

INVA leads this category, winning 7 of 9 comparable metrics.

INVA delivers a 46.5% return on equity — every $100 of shareholder capital generates $46 in annual profit, vs $-84 for PTN. INVA carries lower financial leverage with a 0.23x debt-to-equity ratio, signaling a more conservative balance sheet compared to PRGO's 1.35x. On the Piotroski fundamental quality scale (0–9), ANIP scores 6/9 vs PTN's 2/9, reflecting solid financial health.

MetricPTN logoPTNPalatin Technolog…ANIP logoANIPANI Pharmaceutica…PRGO logoPRGOPerrigo Company p…INVA logoINVAInnoviva, Inc.
ROE (TTM)Return on equity-84.0%+14.5%-50.7%+46.5%
ROA (TTM)Return on assets-53.7%+5.4%-19.8%+32.4%
ROICReturn on invested capital+11.2%+3.7%+14.2%
ROCEReturn on capital employed+9.9%+4.3%+12.4%
Piotroski ScoreFundamental quality 0–92645
Debt / EquityFinancial leverage0.60x1.35x0.23x
Net DebtTotal debt minus cash-$2M$40M$3.4B-$282M
Cash & Equiv.Liquid assets$3M$286M$532M$551M
Total DebtShort + long-term debt$163,781$325M$4.0B$269M
Interest CoverageEBIT ÷ Interest expense-1244.69x1.82x-7.20x63.45x
INVA leads this category, winning 7 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

PTN leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in ANIP five years ago would be worth $21,738 today (with dividends reinvested), compared to $3,986 for PRGO. Over the past 12 months, PTN leads with a +19985.0% total return vs PRGO's -51.2%. The 3-year compound annual growth rate (CAGR) favors PTN at 103.0% vs PRGO's -25.2% — a key indicator of consistent wealth creation.

MetricPTN logoPTNPalatin Technolog…ANIP logoANIPANI Pharmaceutica…PRGO logoPRGOPerrigo Company p…INVA logoINVAInnoviva, Inc.
YTD ReturnYear-to-date+17.8%+7.0%-13.5%+14.7%
1-Year ReturnPast 12 months+19985.0%+18.5%-51.2%+21.7%
3-Year ReturnCumulative with dividends+736.3%+97.1%-58.1%+95.2%
5-Year ReturnCumulative with dividends+35.0%+117.4%-60.1%+94.4%
10-Year ReturnCumulative with dividends+40.0%+84.7%-77.7%+94.9%
CAGR (3Y)Annualised 3-year return+103.0%+25.4%-25.2%+25.0%
PTN leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

INVA leads this category, winning 2 of 2 comparable metrics.

INVA is the less volatile stock with a 0.13 beta — it tends to amplify market swings less than PRGO's 1.18 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. INVA currently trades 90.7% from its 52-week high vs PRGO's 41.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricPTN logoPTNPalatin Technolog…ANIP logoANIPANI Pharmaceutica…PRGO logoPRGOPerrigo Company p…INVA logoINVAInnoviva, Inc.
Beta (5Y)Sensitivity to S&P 5000.20x0.63x1.18x0.13x
52-Week HighHighest price in past year$31.00$99.50$28.44$25.15
52-Week LowLowest price in past year$0.04$56.71$9.23$16.52
% of 52W HighCurrent price vs 52-week peak+61.0%+84.3%+41.2%+90.7%
RSI (14)Momentum oscillator 0–10042.364.460.939.9
Avg Volume (50D)Average daily shares traded15K328K3.4M621K
INVA leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

PRGO leads this category, winning 2 of 2 comparable metrics.

Analyst consensus: ANIP as "Buy", PRGO as "Hold", INVA as "Buy". Consensus price targets imply 70.6% upside for PRGO (target: $20) vs 47.8% for ANIP (target: $124). PRGO is the only dividend payer here at 9.81% yield — a key consideration for income-focused portfolios.

MetricPTN logoPTNPalatin Technolog…ANIP logoANIPANI Pharmaceutica…PRGO logoPRGOPerrigo Company p…INVA logoINVAInnoviva, Inc.
Analyst RatingConsensus buy/hold/sellBuyHoldBuy
Price TargetConsensus 12-month target$124.00$20.00$37.67
# AnalystsCovering analysts103610
Dividend YieldAnnual dividend ÷ price+0.1%+9.8%
Dividend StreakConsecutive years of raises0100
Dividend / ShareAnnual DPS$0.05$1.15
Buyback YieldShare repurchases ÷ mkt cap0.0%+0.7%0.0%+0.2%
PRGO leads this category, winning 2 of 2 comparable metrics.
Key Takeaway

INVA leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). PRGO leads in 2 (Valuation Metrics, Analyst Outlook).

Best OverallInnoviva, Inc. (INVA)Leads 3 of 6 categories
Loading custom metrics...

PTN vs ANIP vs PRGO vs INVA: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is PTN or ANIP or PRGO or INVA a better buy right now?

For growth investors, ANI Pharmaceuticals, Inc.

(ANIP) is the stronger pick with 43. 8% revenue growth year-over-year, versus -100. 0% for Palatin Technologies, Inc. (PTN). Innoviva, Inc. (INVA) offers the better valuation at 6. 9x trailing P/E (11. 9x forward), making it the more compelling value choice. Analysts rate ANI Pharmaceuticals, Inc. (ANIP) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — PTN or ANIP or PRGO or INVA?

On trailing P/E, Innoviva, Inc.

(INVA) is the cheapest at 6. 9x versus ANI Pharmaceuticals, Inc. at 25. 3x. On forward P/E, Perrigo Company plc is actually cheaper at 5. 6x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — PTN or ANIP or PRGO or INVA?

Over the past 5 years, ANI Pharmaceuticals, Inc.

(ANIP) delivered a total return of +117. 4%, compared to -60. 1% for Perrigo Company plc (PRGO). Over 10 years, the gap is even starker: INVA returned +94. 9% versus PRGO's -77. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — PTN or ANIP or PRGO or INVA?

By beta (market sensitivity over 5 years), Innoviva, Inc.

(INVA) is the lower-risk stock at 0. 13β versus Perrigo Company plc's 1. 18β — meaning PRGO is approximately 837% more volatile than INVA relative to the S&P 500. On balance sheet safety, Innoviva, Inc. (INVA) carries a lower debt/equity ratio of 23% versus 135% for Perrigo Company plc — giving it more financial flexibility in a downturn.

05

Which is growing faster — PTN or ANIP or PRGO or INVA?

By revenue growth (latest reported year), ANI Pharmaceuticals, Inc.

(ANIP) is pulling ahead at 43. 8% versus -100. 0% for Palatin Technologies, Inc. (PTN). On earnings-per-share growth, the picture is similar: Innoviva, Inc. grew EPS 816. 7% year-over-year, compared to -1491. 6% for Palatin Technologies, Inc.. Over a 3-year CAGR, ANIP leads at 40. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — PTN or ANIP or PRGO or INVA?

Innoviva, Inc.

(INVA) is the more profitable company, earning 63. 8% net margin versus -107. 4% for Palatin Technologies, Inc. — meaning it keeps 63. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INVA leads at 38. 5% versus -134. 8% for PTN. At the gross margin level — before operating expenses — PTN leads at 99. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is PTN or ANIP or PRGO or INVA more undervalued right now?

On forward earnings alone, Perrigo Company plc (PRGO) trades at 5.

6x forward P/E versus 11. 9x for Innoviva, Inc. — 6. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRGO: 70. 6% to $20. 00.

08

Which pays a better dividend — PTN or ANIP or PRGO or INVA?

In this comparison, PRGO (9.

8% yield) pays a dividend. PTN, ANIP, INVA do not pay a meaningful dividend and should not be held primarily for income.

09

Is PTN or ANIP or PRGO or INVA better for a retirement portfolio?

For long-horizon retirement investors, Innoviva, Inc.

(INVA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 13)). Both have compounded well over 10 years (INVA: +94. 9%, PRGO: -77. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between PTN and ANIP and PRGO and INVA?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: PTN is a small-cap quality compounder stock; ANIP is a small-cap high-growth stock; PRGO is a small-cap income-oriented stock; INVA is a small-cap high-growth stock. PRGO pays a dividend while PTN, ANIP, INVA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

PTN

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 59%
Run This Screen
Stocks Like

ANIP

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 14%
  • Net Margin > 5%
Run This Screen
Stocks Like

PRGO

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 20%
  • Dividend Yield > 3.9%
Run This Screen
Stocks Like

INVA

Quality Mega-Cap Compounder

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 71%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform PTN and ANIP and PRGO and INVA on the metrics below

Revenue Growth>
%
(PTN: -100.0% · ANIP: 29.6%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.